Gufic Biosciences Limited (BOM: 509079)
India
· Delayed Price · Currency is INR 399.75
+7.60 (1.94%)
At close: Sep 10, 2024
Gufic Biosciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | - | 861.36 | 797.05 | 958.4 | 442.32 | 226.88 | Upgrade
|
| Depreciation & Amortization | - | 167.57 | 221.03 | 188.88 | 162.72 | 138.2 | Upgrade
|
| Other Amortization | - | 2.61 | 1.78 | 0.41 | 0.14 | 0.43 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 23 | -0.3 | -0.68 | 0.37 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 0.21 | 0.01 | Upgrade
|
| Other Operating Activities | - | 173.21 | 67.1 | 22.59 | 185.2 | 80.71 | Upgrade
|
| Change in Accounts Receivable | - | -1,532 | -553.16 | -231.93 | -189.9 | -167.18 | Upgrade
|
| Change in Inventory | - | -170.25 | -678.91 | -211.62 | 280.57 | -82.28 | Upgrade
|
| Change in Accounts Payable | - | 400.36 | -120.46 | 336.35 | -9.12 | 274.23 | Upgrade
|
| Operating Cash Flow | - | -74.57 | -265.87 | 1,062 | 872.51 | 471.02 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | 21.76% | 85.24% | 804.52% | Upgrade
|
| Capital Expenditures | - | -1,127 | -1,876 | -874.53 | -123.99 | -398.5 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 45.66 | 0.32 | 0.68 | - | 0.16 | Upgrade
|
| Investment in Securities | - | -10 | -7.77 | - | - | - | Upgrade
|
| Other Investing Activities | - | 67.39 | -23.81 | -72.04 | 57.07 | -26.97 | Upgrade
|
| Investing Cash Flow | - | -1,024 | -1,907 | -945.89 | -66.93 | -425.31 | Upgrade
|
| Short-Term Debt Issued | - | 423.44 | 1,426 | - | - | 51.63 | Upgrade
|
| Long-Term Debt Issued | - | - | 1,075 | 119.71 | 117.89 | 74.77 | Upgrade
|
| Total Debt Issued | - | 423.44 | 2,501 | 119.71 | 117.89 | 126.4 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -60.78 | -731.81 | - | Upgrade
|
| Long-Term Debt Repaid | - | -437.41 | -66.19 | -61.87 | -34.44 | -26.22 | Upgrade
|
| Total Debt Repaid | - | -437.41 | -66.19 | -122.65 | -766.26 | -26.22 | Upgrade
|
| Net Debt Issued (Repaid) | - | -13.98 | 2,435 | -2.94 | -648.37 | 100.18 | Upgrade
|
| Issuance of Common Stock | - | 999.9 | - | - | - | - | Upgrade
|
| Common Dividends Paid | - | -9.72 | -10.44 | -9.21 | -3.63 | -4.88 | Upgrade
|
| Other Financing Activities | - | -152.4 | -81.22 | -50.29 | -134.19 | -137.37 | Upgrade
|
| Financing Cash Flow | - | 823.81 | 2,343 | -62.44 | -786.18 | -42.06 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | -0 | - | 0 | - | -0 | Upgrade
|
| Net Cash Flow | - | -274.65 | 169.94 | 54.07 | 19.4 | 3.65 | Upgrade
|
| Free Cash Flow | - | -1,202 | -2,142 | 187.86 | 748.52 | 72.52 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -74.90% | 932.11% | - | Upgrade
|
| Free Cash Flow Margin | - | -14.89% | -31.01% | 2.41% | 15.35% | 1.91% | Upgrade
|
| Free Cash Flow Per Share | - | -12.20 | -22.09 | 1.94 | 7.72 | 0.93 | Upgrade
|
| Cash Interest Paid | - | 146.8 | 79.06 | 48.09 | 134.19 | 137.35 | Upgrade
|
| Cash Income Tax Paid | - | 270.44 | 276.96 | 330.57 | 94.03 | 101.35 | Upgrade
|
| Levered Free Cash Flow | - | -1,429 | -2,332 | -151.59 | 547.1 | -107.41 | Upgrade
|
| Unlevered Free Cash Flow | - | -1,338 | -2,290 | -126.55 | 620.64 | -28.17 | Upgrade
|
| Change in Net Working Capital | - | 1,201 | 1,358 | 248.18 | -158.94 | 9.18 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.